Structure-based ligand generation commonly assumes a fixed target protein structure, overlooking conformational heterogeneity and the structural adjustments that accompany ligand binding. Modeling protein flexibility remains challenging: matched apo-holo structure pairs are scarce, and pocket-focused methods often omit structural context beyond the binding site. Here, we present FlexiDD (Flexibility-Informed Drug Design), a generative framework for de novo drug design that explicitly models full-protein conformational adaptation at atomic resolution during ligand generation. To address the scarcity of paired apo–holo data, FlexiDD introduces a transferable coordinate denoising strategy that uses coordinate perturbations to bring apo and holo conformations into overlapping noisy distributions. This enables training solely on holo complexes, while supporting both apo and holo inputs at inference. By modeling the full protein rather than isolated binding pockets, FlexiDD incorporates global structural context and constraints into local binding-site adaptation. Experiments on a leakage-audited benchmark demonstrate strong ligand generation performance, with favorable predicted binding affinities and higher PoseBusters validity rates across both holo and apo inputs. Under apo conditioning, FlexiDD achieves 91.6% PoseBusters validity, compared with less than 46.1% for the evaluated baselines that also account for target flexibility. These results demonstrate the potential of holo-only training and full-protein conformational modeling for ligand generation from apo structures, supporting FlexiDD as a practical approach to flexibility-informed structure-based drug design.
Response to Reviewer z1HC
We sincerely thank the reviewer for the thoughtful feedback and helpful question. We appreciate your recognition of the importance of the research problem in drug design and your positive assessment of our theoretical analysis. We have carefully considered your concerns and respond to both points below.
Response: We acknowledge that wet-lab validation is valuable for establishing practical efficacy. Our submission is positioned as an AI methodology contribution, consistent with ICLR’s focus on advances in machine learning and their applications. Specifically, our work focuses on developing a new framework for flexible SBDD and evaluating it through comprehensive computational experiments. We use established computational metrics to assess complementary aspects of ligand generation, including binding affinity estimation (Vina Score/Min), physical plausibility (PB-validity), etc., which are standard metrics adopted across the SBDD literature. This computational evaluation approach is also consistent with prior SBDD studies published at machine learning venues (e.g. TargetDiff[1], ICLR 2023; DecompDiff[2], ICML 2023; IPDiff[3], ICLR 2024; DrugFlow[4], ICLR 2025). Wet-lab validation is beyond the scope of the present methodological study, but remains an important next step toward establishing its practical biological utility. We have clarified this in the manuscript (Apx. C) and identified experimental evaluation of selected generated compounds as future work.
Response: Apo and holo structures of the same protein can exhibit conformation differences (Apx. A.10.3). For an apo–holo pair, adding Gaussian noise at the same scale to both structures reduces the KL divergence between their corrupted coordinate distributions as the noise scale increases (Apx. A.1). Fig. 20 illustrates this effect for one pair: the overlap between the projected pocket-atom densities increases from 81% at σ=1 Å to 96% at the initial inference scale of σ=8 Å (Apx. B.9). The model trained on holo complexes thus learns to denoise from this shared noisy space into holo-like complexes, and is able to generalize to apo inputs at inference. Eq. 19 further provides a theoretical bound on the discrepancy between the resulting output distributions under the stated assumptions.
During sampling process, our method does not explicitly enforce identical outputs from paired apo and holo inputs. In both cases, denoising is guided by the same fixed protein sequence. Our goal is to generate plausible protein–ligand complexes from either apo or holo input conformation.
Reference
[1] "3D Equivariant Diffusion for Target-Aware Molecule Generation and Affinity Prediction", ICLR 2023
[2] "DecompDiff: Diffusion Models with Decomposed Priors for Structure-Based Drug Design", ICML 2023
[3] "Protein-ligand interaction prior for binding-aware 3d molecule diffusion models", ICLR 2024
[4] "Multi-domain distribution learning for de novo drug design." ICLR 2025